What is TCMD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.51B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TCMD?

P/E (TTM) is 20.32 and 52-week range is $14.00 to $37.77 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TCMD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TCMD?

The company profile lists revenue (TTM) near $343M, net income (TTM) near $24M, EPS (TTM) near $1.08 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Tactile Systems Technology Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Minneapolis, Minnesota, US, 22.6M shares outstanding, ISIN US87357P1003 when available from company profile and filing metadata.

Tactile Systems Technology Inc

$TCMD

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$22.44

+1.45%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 1,086 full-time employees. The company went IPO on 2016-07-28. The firm's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. The company is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. The company markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The company also offers Kylee, a free mobile application that helps patients learn about lymphedema.

Employees

1,086

Website

www.tactilemedical.com/

IPO

2016-07-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)